Strand, MRIGlobal collaborate on infectious disease diagnostics

Partners to collaborate globally to co-develop mobile clinical genomic testing labs, and develop companion diagnostics for oncology and other diseases.


(L-R) Mr Ranganathan Shashidhar, senior scientific consultant, MRIGlobal; Dr Kay van der Horst, VP, research, development, testing and engineering operations, MRIGlobal; Dr Vijay Chandru, chairman & CEO, Strand Life Science; Dr Eric Van Gieson, senior director, biosurveillance & diagnostics programs, MRIGlobal; Dr Sudhir Borgonha, medical director, Strand Life Sciences

Bangalore-based Strand Life Sciences entered into a partnership with US-based MRIGlobal, an independent non-profit organization performing contract research for government and industry.

The partnership is said to be an important step in the right direction towards enabling a focussed area of development and validation of tests for infectious disease diagnosis.

Strand and MRIGlobal will work towards successfully co-developing complex and high-end diagnostics.

At a global level, Strand and MRIGlobal will conduct joint R&D to integrate Strand SmartLab, which delivers NGS-based diagnostic lab and informatics solutions for oncology and other diseases, with MRIGlobal's Mobile Labs, which are deployed in resource-limited environments, to enable rapid disease diagnosis.

Mr Kay van der Horst, VP, research, development, engineering & testing operation, MRIGlobal, said, "In the last 10 years, there has been biosecurity threats, natural disasters, and the emergence of H1N1, SARS and Ebola. We emphasize on taking the knowledge and creating diagnostics solutions, and bringing knowledge in to public health response and preparedness along with innovating next-generation diagnostics solutions."


Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email